A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

BACKGROUND: Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with drug-drug interactions. Since both cardiovascular and renal disease, and poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwuji, Collins C., Churchill, Duncan, Bremner, Stephen, Perry, Nicky, To, Ye, Lambert, Debbie, Bruce, Chloe, Waters, Laura, Orkin, Chloe, Geretti, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370264/
https://www.ncbi.nlm.nih.gov/pubmed/32689975
http://dx.doi.org/10.1186/s12879-020-05240-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370264/
https://www.ncbi.nlm.nih.gov/pubmed/32689975
http://dx.doi.org/10.1186/s12879-020-05240-y

Ejemplares similares